Emily M. Leproust, the Chief Executive Officer of Twist Bioscience Corp (NASDAQ:TWST), recently sold a portion of her holdings in the company. According to a recent SEC filing, Leproust sold 546 shares of common stock at an average price of $45.5911 per share, totaling approximately $24,892. Following this transaction, she holds 672,518 shares directly. The stock, which has shown a strong 34% return over the past year according to InvestingPro data, currently trades above its Fair Value.
The sale was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units, as mandated by the company's equity incentive plans. This transaction was not a discretionary trade by Leproust. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 4.88, while offering investors access to 7 additional key insights and a comprehensive Pro Research Report covering what matters most about this $2.72B market cap company.
In other recent news, Twist Bioscience reported robust earnings and revenue results, with Q4 revenue climbing 27% year-over-year to $84.7 million and annual revenue of $330 million, marking a 28% growth. Financial analysis firm Baird maintained an Outperform rating on Twist Bioscience and increased its price target to $48.00, while TD Cowen reaffirmed a Buy rating with a price target of $58.00. Scotiabank (TSX:BNS) also raised its price target for the company to $54, maintaining a Sector Outperform rating.
These recent developments indicate strong confidence in Twist Bioscience's financial performance and future prospects. The company exceeded its gross margin guidance for the quarter, achieving 45.1%, and saw an annual gross margin improvement to 42.6%. For fiscal year 2025, the company anticipates revenue growth between 17% to 20% year-over-year, largely driven by the Next (LON:NXT) Generation Sequencing (NGS) and Synthetic Biology (SynBio) sectors. The company also received a $15 million upfront payment from Xoma (NASDAQ:XOMA) as part of a royalty purchase agreement, further bolstering its financial position.
Analysts from Baird, TD Cowen, and Scotiabank all expressed optimism based on Twist Bioscience's strong financial guidance, innovative approach, and market demand for its services. These facts underscore the company's strong financial position and potential for continued growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.